Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.

Autor: Pant S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hamilton E; Breast and Gynecologic Research Program, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA., Ulahannan SV; Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA.; Department of Internal Medicine, Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Strauss JF; Mary Crowley Cancer Research, Dallas, Texas, USA., Braiteh FS; Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, Nevada, USA., Huang M; Merck & Co., Inc., Rahway, New Jersey, USA., Liaw DCH; Merck & Co., Inc., Rahway, New Jersey, USA.

Publikováno v: Cancer [Cancer] 2023 Jun 15; Vol. 129 (12), pp. 1919-1929. Date of Electronic Publication: 2023 Mar 27.